glp 1 receptor agonist contraindications Incretins: How we got here, where we're at and what is coming next Table 5 from Glucagon-Like Peptide-1

Clinical data suggests Wegovy causes slightly lower rates of gastrointestinal side effects compared to Zepbound

While these questions remain unanswered, one thing is clear: GLP-1RAs challenge the conventional approach to AUD treatment, offering an avenue that aligns more closely with real-world drinking behaviors and patient needs

This means that is not well studied currently, there is no reliable information on the safety and side effects of microdosing GLP-1, and there are no guidelines on how microdosing should occur

Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations

Notably, DPP-4 inhibitors appear to be safe regarding the risk of fractures, as they tend to decrease this risk, but more clinical trials are needed to explore the effects of DPP-4 inhibitors in other populations beyond T2DM